GEM-DeCan: Improving tumor immune microenvironment profiling by the integration of novel gene expression and DNA methylation deconvolution signatures

Ting Xie,Julien Pernet,Nina Verstraete,Miguel Madrid-Mencía, Mei-Shiue Kuo, Alexis, Hucteau,Alexis Coullomb, Jacobo Solórzano, Olivier Delfour, Francisco Cruzalegui, Vera, Pancaldi

semanticscholar

引用 0|浏览1
暂无评分
摘要
Quantifying the proportion of the different cell types present in tumor biopsies remains a priority in cancer research. So far, a number of deconvolution methods have emerged for estimating cell composition using reference signatures either based on gene expression or on DNA methylation from purified cells. These two deconvolution approaches could be complementary to each other, leading to even more performant signatures, in cases where both data types are available. However, the potential relationship between signatures based on gene expression and those based on DNA methylation remains underexplored. Here we present five new deconvolution signature matrices, based on DNA methylation or RNAseq data, which can estimate the proportion of immune cells and cancer cells in a tumour sample. We test these signature matrices on available datasets for in-silico and in-vitro mixtures, peripheral blood, cancer samples from TCGA, bone marrow from multiple myeloma patients and a single-cell melanoma dataset. Cell proportions estimates based on deconvolution performed using our signature matrices, implemented within the EpiDISH framework, show comparable or better correlation with FACS measurements of immune cell-type abundance and with various estimates of cancer sample purity and composition than existing methods. Finally, using publicly available data of 3D chromatin structure in haematopoietic cells, we expanded the list of genes to be included in the RNAseq signature matrices by considering the presence of methylated CpGs in gene promoters or in genomic regions which are in 3D contact with these promoters. Our expanded signature matrices have improved performance compared to our initial RNAseq signature matrix. Finally, we show the value of our signature matrices in predicting patient response to immune checkpoint inhibitors in three melanoma and one bladder cancer cohort, based on bulk tumour sample gene expression data. We also provide GEM-DeCan: a snakemake pipeline, able to run an analysis from raw sequencing data to deconvolution based on various gene expression signature matrices, both for bulk RNASeq and DNA methylation data. The code for producing the signature matrices and reproducing all the figures of this paper is available on GitHub: https://github.com/VeraPancaldiLab/GEMDeCan.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要